TherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of “Buy” from Brokerages
TherapeuticsMD Inc (NYSEMKT:TXMD) has earned an average recommendation of “Buy” from the eight brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $17.50.
Several equities research analysts have issued reports on TXMD shares. BidaskClub cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Wednesday, September 27th. Oppenheimer Holdings, Inc. raised shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. Finally, Morgan Stanley started coverage on shares of TherapeuticsMD in a research note on Friday, September 8th. They set an “equal weight” rating and a $6.00 price target on the stock.
TherapeuticsMD (NYSEMKT TXMD) opened at 4.82 on Thursday. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30. The firm’s 50-day moving average is $4.96 and its 200-day moving average is $4.96. The stock’s market capitalization is $983.41 million.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.